Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic advances: beta-interferon for multiple sclerosis

W Clark1

  • 1Department of Pharmacy Policy and Practice, Keele University, Staffs.

Journal of Clinical Pharmacy and Therapeutics
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Participatory Development of a Suicide Prevention Program for Autism Community Organizations.

OTJR : occupation, participation and health·2025
Same author

Effect of Photo-polymerization Delay on the Bond Strength and Microhardness of Dual-polymerizing Resin Cements.

Operative dentistry·2023
Same author

A RAC-GEF network critical for early intestinal tumourigenesis.

Nature communications·2021
Same author

On Sub-Soil Drainage, by Mr. Clark, C.E.

The Indian medical gazette·2017
Same author

Evaluating the success of a marine protected area: A systematic review approach.

Journal of environmental management·2016
Same author

Isolation, identification and characterisation of ballan wrasse Labrus bergylta plasma pigment.

Journal of fish biology·2016
Same journal

Impact of pharmacist-initiated educational interventions on improving medication reconciliation practice in geriatric inpatients during hospital admission in Vietnam.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Evaluation of off-label anti-vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion in Turkey.

Journal of clinical pharmacy and therapeutics·2022
Same journal

A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Effects of caregiver counselling on medication persistence and adherence in patients with dementia at a pharmacist-managed clinic: A pilot study.

Journal of clinical pharmacy and therapeutics·2022
Same journal

The 50% and 95% effective doses of remimazolam tosilate with adjuvant sufentanil for sedation in patients with liver cirrhosis undergoing oesophagogastric varices screening endoscopy.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Tumour necrosis factor inhibitor combined with intravenous immunoglobulin and heparin for treatment of recurrent spontaneous abortion: A two-centre, retrospective, cohort study.

Journal of clinical pharmacy and therapeutics·2022
See all related articles

Beta-interferon shows a small benefit for multiple sclerosis (MS) patients but is not a cure. The high cost and limited effectiveness present challenges for managing MS treatment.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) is a debilitating neurological disease with no effective cure.
  • Current treatments offer limited benefits for patients with relapsing-remitting MS.

Purpose of the Study:

  • To evaluate the efficacy and clinical significance of beta-interferon therapy in patients with multiple sclerosis.
  • To inform decisions regarding the management and introduction of beta-interferon drugs.

Main Methods:

  • Two randomized, double-blind, placebo-controlled trials were conducted.
  • Participants included mildly disabled patients diagnosed with relapsing-remitting MS.

Main Results:

  • Beta-interferon demonstrated a small positive effect on disease progression.

Related Experiment Videos

  • The clinical significance of this observed benefit remains uncertain.

    • Conclusions:

    • Beta-interferon is not a curative treatment for MS.
    • The high cost and modest efficacy necessitate careful consideration for widespread clinical adoption and resource allocation.